Ophthalmic assessments are no longer mere box-checks in clinical trials. With advanced imaging and endpoints becoming the norm, sponsors must grapple with complexity and risk that extend well beyond...
Read More
For many sponsors, the full meaning of “ophthalmic assessments” might remain an afterthought until those requirements start complicating site setup, timelines, budget, or patient enrollment. Yet...
Read More
Recent research analyzing over 424,000 patients has revealed an association between semaglutide—a widely used medication for type 2 diabetes and weight management—and an increased risk of developing...
Read More
In 2025, sponsors and CROs are under mounting pressure to maximize return on investment (ROI), streamline processes, and deliver results without delays. While advancements in artificial intelligence...
Read More
In September 2024, the FDA released its finalized guidance on Conducting Clinical Trials with Decentralized Elements (DCTs). This guidance clarifies and refines recommendations for integrating...
Read More
Boston, MA, November 2024 – 20/20 Onsite continues to expand at the forefront of clinical research, delving deeper into the critical intersection of neurology and ophthalmology. With a growing number...
Read More
16 Oct. 2024 ( Business Weekly). A UK-US first ‘hi-tech EyeTech’ partnership has been unveiled by Cambridge’s Sano Genetics and American duo 20/20 Onsite in Everett, Massachusetts and Clinical...
Read More
The complexity and high costs associated with clinical trials make efficiency a top priority. With patient recruitment challenges, site management issues, and the need for high-quality data, many...
Read More